HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VPC23019

inhibits S1P3 receptor; structure in first source

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Neutral Amino Acids: 200
    - Serine: 6037
      - Phosphoserine: 111
        VPC23019: 6
  - Phosphoamino Acids: 1
    - Phosphoserine: 111
      - VPC23019: 6

Experts

1.	Gong, Wenjing: 1 article (11/2018)
2.	Liu, Aina: 1 article (11/2018)
3.	Qu, Huajun: 1 article (11/2018)
4.	Wang, Zhihua: 1 article (11/2018)
5.	Dokuni, Ryota: 1 article (01/2018)
6.	Kamiryo, Hiroshi: 1 article (01/2018)
7.	Katsurada, Masahiro: 1 article (01/2018)
8.	Kawa, Yoshitaka: 1 article (01/2018)
9.	Kobayashi, Kazuyuki: 1 article (01/2018)
10.	Nagano, Tatsuya: 1 article (01/2018)

Related Diseases

1.	Necrosis 01/01/2010 - "Moreover, isoflurane-mediated protection against H(2)O(2)-induced necrosis of HK-2 cells was significantly attenuated by an S1P(1/3) receptor antagonist, VPC23019, and by SK inhibitors DMS or 4-[[4- (4-chlorophenyl)-2-thiazolyl]amino]phenol. "
2.	Glucose Intolerance 01/01/2023 - "We previously demonstrated that blockade of S1P2 signaling in S1P2-deficient mice attenuates high-fat diet-induced adipocyte hypertrophy and glucose intolerance and an S1P2-specific antagonist JTE-013 inhibits, whereas an S1P1/S1P3 dual antagonist (VPC23019) activates, adipogenic differentiation of preadipocytes. " 01/01/2023 - "Based on those observations, this study examined whether an S1P1-specific agonist, SEW-2871, VPC23019, or their combination acts on obesity and glucose intolerance in leptin-deficient ob/ob mice. "
3.	Obesity 01/01/2023 - "Based on those observations, this study examined whether an S1P1-specific agonist, SEW-2871, VPC23019, or their combination acts on obesity and glucose intolerance in leptin-deficient ob/ob mice. "
4.	Neoplasms (Cancer) 11/01/2018 - "Overexpressed miR-330-3p in MKN1 cells repressed SPHK1 and S1PR1 expressions like their chemical inhibitors-SPHK1 inhibitors (FTY720) and S1PR1 inhibitors (VPC23019), and acted anti-tumor both in vitro and in vivo. " 01/01/2010 - "Disrupting this concentration difference by S1P receptor agonists and antagonists like FTY720, SEW2871, and VPC23019, by an anti-S1P antibody, or by inhibiting the S1P-lyase has therapeutic potential for autoimmune diseases like multiple sclerosis (MS) and rheumatoid arthritis and for many other disorders like cancer, fibrosis, inflammation, macular degeneration, diabetic retinopathy, and glaucoma. "
5.	Inflammation (Inflammations) 01/01/2018 - "Upon OVA challenge, VPC23019 exhibited substantially attenuated eosinophilic inflammation. " 01/01/2010 - "Disrupting this concentration difference by S1P receptor agonists and antagonists like FTY720, SEW2871, and VPC23019, by an anti-S1P antibody, or by inhibiting the S1P-lyase has therapeutic potential for autoimmune diseases like multiple sclerosis (MS) and rheumatoid arthritis and for many other disorders like cancer, fibrosis, inflammation, macular degeneration, diabetic retinopathy, and glaucoma. "

Related Drugs and Biologics

1.	Isoflurane
2.	Phenol (Carbolic Acid)
3.	SEW2871
4.	Leptin
5.	Sphingosine-1-Phosphate Receptors
6.	Fingolimod Hydrochloride (FTY720)
7.	JTE 013
8.	N,N-dimethylsphingosine
9.	sphingosine kinase